Biolegend, 639754, Ultra-LEAF™ Purified anti-human CD226 (DNAM-1) Antibody, 1mg

DNAM-1, also known as CD226, was first identified as T lineage-specific activation antigen (TLiSA) and subsequently renamed as Platelet and T-cell activation antigen 1 (PTA). DNAM-1 consists of two Ig-like domains on its extracellular portion, a transmembrane region and a cytoplasmic region containing binding motifs for members of band 4.1 family and membrane-associated guanylate kinase homolog (MAGUK) family. DNAM-1 is predominantly expressed on cell surface of T cells, NK cells, monocytes/ macrophages, platelets and megakaryocytes and a subset of B cells. DNAM-1 serves as a signaling-transducing adhesion molecule, and is physically and functionally associates with LFA-1 (CD11a/CD18) on NK and T cells. The clustering of LFA-1 induces Fyn-mediated phosphorylation of DNAM-1 and signaling. Evidence suggests that DNAM-1 is involved in NK and T cell-mediated cytotoxicity (CTL) against ligand-expressing tumor cells. Two ligands for DNAM-1 have been identified, the poliovirus receptor (PVR/CD155) and its family member nectin-2 (PRR/CD112), which are located at cell junctions and broadly expressed on epithelial, endothelial and neuronal cells. Additionally, DNAM-1 regulates monocyte extravasation through PVR expressed by endothelial cells. It has been reported that DNAM-1 is specifically expressed on differentiated Th1 cells, but not to Th2 or Th0 cells. Antibody blocking assay demonstrates that DNAM-1 may play a role in polarization of T cells, activation and effectors of Th1 cells. PVRIG (CD112R) is identified as a novel immune checkpoint to inhibit T cell response by competing DNAM-1 with CD112.
1mg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Recombinant Human DNAM-1/CD226-Fc Chimera
Formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level: Less than 0.01 EU/μg of the protein (< 0.001 ng/μg of the protein) as determined by the LAL test
Preparation: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration: The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application: Block - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by blocking the binding of 0.2 µg/mL recombinant biotinylated human CD155-Fc chimera (Cat. No 796604) to immobilized 1 µg/mL recombinant human DNAM-1/CD226-Fc chimera (Cat. No. 773606). ND50 range: 0.02 - 0.15 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.
RRID: AB_3662324 (BioLegend Cat. No. 639753) AB_3662324 (BioLegend Cat. No. 639754)
Structure: Disulfide bond-linked homodimer, Ig domain containing adhesion molecule
Distribution: Peripheral blood T cells, NK cells, monocytes/macrophages, platelets and megakaryocytes and a subset of B cells; plasma membrane
Function: It is involved in intercellular adhesion, lymphocyte signaling, cytotoxicity and lymphokine secretion mediated by cytotoxic T-lymphocyte (CTL) and NK cells.
Interaction: Epithelial, endothelial and neuronal cells; LFA-1
Ligand/Receptor: PVR (CD155) and Nectin-2 (CD112)
Cell Type: B cells, Macrophages, Monocytes, NK cells, T cells, Th1
Biology Area: Immunology
Molecular Family: Adhesion Molecules, CD Molecules
Antigen References: Fuchs A, Colonna M. 2006. Semin Cancer Biol. 16:359-66. Kojima H, et al. 2003. J Biol Chem. 278:36748-53. Burns GF, et al. 1985. J Exp Med. 161:1063-78. Scott JL, et al. 1989. J Biol Chem. 264:13475-82. Shibuya A, et al. 1996. Immunity. 4:573-81. Shibuya K et al. 1999. Immunity. 11:615-23. Ralston KJ, et al. 2004. J Biol Chem. 279:33816-28. Tahara-Hanaoka S, et al. 2006. Blood. 107:1491-6. Bottino C, et al. 2003. J Exp Med. 198:557. Reymond N, et al. 2004. J Exp Med. 199:1331-41. Dardalhon V, et al. 2005. J Immunol. 175:1558-65. Shibuya K, et al. 2003. J Exp Med. 198:1829-39.
Gene ID: 10666
UniProt: View information about CD226 on UniProt.org
Clone: W21097B
Regulatory Status: RUO
Other Names: CD226, Platelet and T-cell activation antigen 1, PTA1, T lineage specific activation antigen 1 antigen
Isotype: Rat IgG2b, κ
Q: Do you guarantee that your antibodies are totally pathogen free?
A: BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
Q: Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
A: No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
Q: Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
A: No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.
Q: Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
A: We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.